Purchasing Commitments Must Underpin US Expansion
AAM Industry Association Sets Out Blueprint For US Supply Chain
In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.
You may also be interested in...
Phlow CEO Reveals Possible Partnerships With ‘Global Generics Manufacturing Companies’
In the second part of an exclusive interview with Generics Bulletin, Phlow CEO Eric Edwards has revealed that the company is at the precipice of entering into agreements to co-develop essential medicines in the US. Edwards has also recognized the Biden administration’s efforts to secure domestic supply, offering suggestions on how to fix “America’s broken supply chain.”
AAM CEO ‘Not Fully Aligned With Biden Administration On Pay-For-Delay Ban’
In an exclusive interview with Generics Bulletin, US Association for Accessible Medicines CEO Dan Leonard has expressed concerns over the blanket change to patent settlements introduced by Joe Biden’s recent executive order. Furthermore, Leonard expects to see a “robust decade” for generic drugs, biosimilars and complex generics as many major brands are set to lose their exclusivity.
Lupin CEO Says Additional incentives Needed To Make US Manufacturing Viable
Lupin CEO Vinita Gupta has insisted that additional incentives are necessary to make local manufacturing in the US viable. The recently-launched podcast by the US Association for Accessible Medicines, with CEO Dan Leonard as the host, welcomed Gupta who shared details of Lupin’s strategy and how the company plans to keep a firm foot in affordable medicines.